CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Zacks News
Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies
by Zacks Equity Research
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $45.28, moving +0.11% from the previous trading session.
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
by Zacks Equity Research
Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
by Zacks Equity Research
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
by Zacks Equity Research
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
by Zacks Equity Research
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
by Zacks Equity Research
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
by Zacks Equity Research
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
by Zacks Equity Research
CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.06, marking a +1.35% move from the previous day.
Here's Why You Should Add CRISPR Stock to Your Portfolio
by Zacks Equity Research
CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.
4 Biotech Stocks to Consider for Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
by Zacks Equity Research
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
by Zacks Equity Research
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
by Zacks Equity Research
Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.92, moving -0.51% from the previous trading session.
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
by Zacks Equity Research
Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
by Zacks Equity Research
Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.